GlassScriptPhysician profile
Raymond N Broughton
NPI 1790734788
$1,448.99
in general payments reported to CMS, 2019-2025
25 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $29.85 · 2021: $143 · 2022: $72.99 · 2023: $287 · 2024: $51.78 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.04 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $361.75 | 2019-2023 | |
| Abbvie INC. | $157.75 | 2021-2025 | Vraylar |
| Amarin Pharma, INC. | $125.78 | 2019 | |
| Neurocrine Biosciences, INC. | $114.57 | 2025 | |
| Alkermes, INC. | $86.10 | 2025 | Aristada, Lybalvi |
| Galt Pharmaceuticals, LLC | $77.79 | 2023 | Orphengesic Forte |
| Otsuka America Pharmaceutical, INC. | $61.92 | 2025 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.78 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $54.63 | 2022 | |
| Procept Biorobotics Corporation | $50.92 | 2025 | |
| Pfizer INC. | $47.72 | 2019-2021 | |
| Gilead Sciences, INC. | $33.74 | 2021-2024 | |
| Cranial Technologies, INC | $23.63 | 2025 | Doc Band |
| Abbott Laboratories | $23.29 | 2021 | |
| Sanofi Pasteur INC. | $20.89 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $19.47 | 2024 | |
| Amgen INC. | $19.30 | 2023 | Otezla, Repatha |
| Mannkind Corporation | $18.36 | 2022 | |
| Millicent US INC | $17.25 | 2025 | Intrarosa, Femlyv |
| Horizon Therapeutics Plc | $16.42 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $13.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Broughton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.